Rentschler Biopharma has commenced construction on its new production site, adjacent to its existing site in Milford, Massachusetts, the US.
The new 22,000ft2 facility, named Rentschler Biopharma Manufacturing Center US (RBMC US), will house four new 2,000l single-use bioreactors.
Go deeper with GlobalData
It will expand the company’s cGMP manufacturing capacity and accelerate the clinical and commercial supply of biopharmaceuticals.
The new facility’s design features upstream ballroom processing sized for production flexibility and can also accommodate future adaptations to increase capacity.
The company stated that the site will also include expanded quality control (QC), development, and warehousing capabilities.
See Also:
RBMC US will provide digital and analytical services that include advanced analytics yield optimisation, augmented/virtual reality-enabled operations and no-touch batch releases.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataRentschler Biopharma CEO Frank Mathias said: “With Rentschler Biopharma’s contribution to the production of mRNA vaccines to beat the COVID-19 virus, we have seen firsthand how important it is to have highly adaptable capacity and to have the experience and expertise needed to produce new therapeutic modalities, fast.
“The U.S. expansion we have kicked off at the groundbreaking is part of our ongoing plan to strategically grow our business as we support our clients in developing and manufacturing even highly complex molecules.
“We must always be ready to meet the ongoing and ever-changing challenges of reliably bringing new treatments to patients.”
Slated to commence operations in late 2023, the new facility will add space for manufacturing and enables the US operations to centralise support services to produce essential biopharmaceuticals.
The company said that its existing Milford facility has been changed from a single-product commercial facility to multiple-products facility with up to 500l bioreactor.
———————————————————————————————————————
Rentschler Biopharma breaks ground on new production facility in Massachusetts. Credit: Rentschler Biopharma SE.
